CSCristiana Stefan

Cristiana Stefan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cristiana Stefan has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Npp1

    by Cristiana Stefan, Maarten Van Acker, Mathieu Bollen

  • Npp2

    by Silvia Jansen, Cristiana Stefan, Mathieu Bollen

  • Open Access

    Modulation of purinergic signaling by NPP-type ectophosphodiesterases

    by Cristiana Stefan, Silvia Jansen, Mathieu Bollen

    Extracellular nucleotides can elicit a wide array of cellular responses by binding to specific purinergic receptors. The level of ectonucleotides is dynamically controlled by their release from cells, synthesis by ectonucleoside diphosphokinases and ectoadenylate kinases, and hydrolysis by ectonucleotidases. One of the four structurally unrelated families of ectonucleotidases is represented by the NPP-type ectophosphodiesterases. Three of the seven members of the NPP family, namely NPP1–3, are known to hydrolyze nucleotides. The enzymatic action of NPP1–3 (in)directly results in the termination of nucleotide signaling, the salvage of nucleotides and/or the generation of new messengers like ADP, adenosine or pyrophosphate. NPP2 is unique in that it hydrolyzes both nucleotides and lysophospholipids and, thereby, generates products that could synergistically promote cell motility. We review here the enzymatic properties of NPPs and analyze current evidence that links their nucleotide-hydrolyzing capability to epithelial and neural functions, the immune response and cell motility.


  • Open Access

    Imatinib Mesylate Inhibits Glucose Uptake in Gastrointestinal Stromal Tumor Cells by Downregulation of the Glucose Transporters Recruitment to the Plasma Membrane

    by Hans Prenen, Cristiana Stefan, Bart Landuyt, Peter Vermaelen, Maria Debiec-Rychter, Mathieu Bollen, Sigrid Stroobants, Ernst de Bruijn, Luc Mortelmans, Raf Sciot, et al.

    Imatinib mesylate, the inhibitor of the KIT protein tyrosine kinase that is constitutively activated in Gastrointestinal Stromal Tumors (GISTs), has been established as the first highly effective drug in the treatment of patients with advanced GISTs. Recent studies suggest that changes in the glucose metabolism could be an additional mechanism of the anti-proliferative action of imatinib. The aim of this study was to investigate the effect on glucose flux and metabolism in a human GIST882 cell line after exposure to imatinib. Imatinib induced a concentration-dependent inhibition of cell proliferation in GIST882 cells (IC50, 0.030 ± 0.006 μM). By 18F-FDG uptake measurements, after 24 h exposure to the drug at concentrations of 0.03 μM and 0.3 μM, the glucose uptake decreased by ~25% and ~95%, respectively. Moreover, after a 3-h treatment at the concentration of 0.3 μM of imatinib the decrease in glucose-uptake was already more than 50%. After 24-h of treatment with 0.3 μM imatinib, the measurements of the hexokinase and glucose-6-phosphate dehydrogenase activity revealed a 30% and 37% decrease, respectively. Western blotting disclosed mainly expression of glucose transporter GLUT-2 in GIST cells. Exposure of GIST cells to imatinib resulted in the decline of the GLUT-2 receptor recruitment to cell membrane, which paralleled with the elevated amount of the total KIT protein. These findings suggest that a rapid decline in glucose uptake following imatinib treatment in GIST cells is dependent on glucose transporter impaired anchorage to the plasma membrane, with the subsequent recruitment of KIT protein.


  • Threonine Autophosphorylation and Nucleotidylation of the Hepatic Membrane Protein PC‐1

    by Cristiana Stefan, Willy Stalmans, Mathieu Bollen

    The membrane protein plasma-cell-differentiation antigen 1 (PC-1) has been described as a phosphodiesterase-I/nucleotide pyrophosphatase and as an autophosphorylating protein kinase. It has been suggested, however, that PC-1 is not a real protein kinase and that the autophosphorylated enzyme represents a nucleotidylated derivative, which is formed on Thr238 (murine PC-1) as a catalytic intermediate during ATP hydrolysis [Belli, S.I., Mercuri, F.A., Sali, A.& Goding, J.W. (1995) Eur. J. Biochem. 228, 669-676]. We have investigated the proposed multifunctional role of PC-1 and show here that ATP hydrolysis and autophosphorylation represent two distinct catalytic reactions. The enzyme was radiolabeled when various concentrations (1-260 microM) of [alpha-32P]ATP or [alpha-32P]ADP, but not [gamma-32P]ATP, were used as substrates for the formation of the pyrophosphatase catalytic intermediate, especially in the presence of imidazole, which interferes with the hydrolysis of the nucleotidylated enzyme. In contrast, autoradiography revealed autophosphorylation only with [gamma-32P]ATP as the phosphoryl donor, and autophosphorylation has been shown to occur only at ATP concentrations below 5 microM. Autophosphorylation could also be differentiated from nucleotidylation by its higher resistance to alkaline treatment and its more basic pH optimum. An intestinal nucleotide pyrophosphatase with a structurally related catalytic site could not be autophosphorylated, which shows that autophosphorylation is not an intrinsic property of the nucleotide pyrophosphatase reaction. Autophosphorylation of PC-1 was associated with inactivation of its phosphodiesterase-I/nucleotide-pyrophosphatase activity. We propose that autophosphorylation of PC-1 on Thr238 at low ATP concentrations serves as an autoregulatory mechanism that makes Thr238 unavailable for participation in the hydrolysis of extracellular nucleotides when they become scarce.